Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome

J Allergy Clin Immunol. 2020 Jun;145(6):1681-1686.e5. doi: 10.1016/j.jaci.2019.12.909. Epub 2020 Jan 12.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Schnitzler Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • canakinumab